Profitability
Weight: 25%
F
20
- 5yr Avg ROIC 3.8%
- Operating Margin Trend -6.59 pp/yr
LGND
Ligand Pharmaceuticals Incorporated
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 2 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
22
- 5yr Avg ROE 3.9%
- 5yr Share-Count CAGR 4.2%
Growth Quality
Weight: 25%
B-
62
- 5yr Revenue CAGR 2.6%
- 5yr EPS CAGR 16.4%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 20%
B+
76
- 5yr FCF Margin 30.3%
- 5yr FCF/NI Conversion 0.51x
Balance Sheet
Weight: 10%
A+
100
- Net Debt / EBITDA -1.46x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 6.78
Stability
Weight: 5%
D
35
- EPS Volatility (σ/μ) 1.19
- Piotroski F-Score 6
- Negative-Revenue Years (5) 2/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 3 gurus held; 2 trimmed; 2 full exits.
- Holders
- 2 -1
- Avg Δ position
- -63.2%
- New buys
- 0
- Full exits
- 2